Entity

Matrix Biotek

Biotechnology - Therapeutics and Diagnostics

Matrix Biotek, founded in Barcelona in 2025, is the independent European hub of the Matriks Biotek group (Ankara, 2002). The company delivers advanced expertise in biologic drug monitoring and diagnostics. Its portfolio includes 126 SHIKARI® ELISA kits for 44 biologics, 16 CORONAHUNTER® COVID-19 kits, and custom ELISA development services. Matrix Biotek SL follows the group’s values of innovation, scientific quality, and global health. Matriks Biotek was the first worldwide to commercialize biological drug monitoring kits and exports over 95% of its production to more than 40 countries, supported by more than 200 publications. From Barcelona, Matrix Biotek SL leads R&D&I in infectious diseases (notably invasive Candida), inflammation and IBD, oxidative stress, autoimmunity, post-COVID-19 vascular disorders, and tailored ELISA assays. The company works with leading partners, including LEITAT, co-developing an ELISA kit for Human S100A12 quantification.

+34 675 139 431

halukataoglu@matriksbiotek.com

matriksbiotek.com


Contact person: Haluk Ataoglu

Location: Torre I - 04B7